Publicacions en col·laboració amb investigadors/es de Hospital Severo Ochoa (23)

2024

  1. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry

    United European Gastroenterology Journal

2023

  1. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease

  2. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry

    Digestive and Liver Disease, Vol. 55, Núm. 3, pp. 350-359

  3. Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis: Predictive Factors and Long-Term Step-Down Efficacy

    Journal of pediatric gastroenterology and nutrition, Vol. 76, Núm. 2, pp. 191-198

2022

  1. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry

    United European Gastroenterology Journal, Vol. 10, Núm. 5, pp. 507-517

  2. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe

    Therapeutic Advances in Gastroenterology, Vol. 15

  3. Long-term medical treatment efficacy in patients with eosinophilic oesophagitis and oral food immunotherapy

    Clinical and Experimental Allergy

  4. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions

    Journal of Asthma and Allergy, Vol. 15, pp. 281-302

2021

  1. Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study (European Journal of Pediatrics, (2021), 180, 9, (3029-3038), 10.1007/s00431-021-04063-6)

    European Journal of Pediatrics

  2. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy

    Clinical Gastroenterology and Hepatology, Vol. 19, Núm. 10, pp. 2046-2053.e2

  3. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study

    European Journal of Pediatrics, Vol. 180, Núm. 9, pp. 3029-3038

2020

  1. Recommendations for the diagnosis and practical management of paediatric eosinophilic oesophagitis

    Anales de Pediatria, Vol. 92, Núm. 6, pp. 376.e1-376.e10

2019

  1. CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis

    Journal of Pediatric Gastroenterology and Nutrition

2018

  1. Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 67, Núm. 2, pp. 210-216

  2. The role of proton pump inhibitors in the management of pediatric eosinophilic esophagitis

    Frontiers in Pediatrics

2016

  1. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 62, Núm. 5, pp. 704-710

2011

  1. Una nueva terapia para la esofagitis eosinofílica: Budesonida viscosa oral

    Anales de Pediatria

2009

  1. Esofagitis herpética como causa de disfagia aguda

    Anales de Pediatria

2006

  1. Colestasis como forma atípica de presentación de infección por virus de Epstein-Barr

    Anales de Pediatria

  2. Manifestacíon atípica de infección por «Salmonella enteritidis»

    Acta Pediatrica Espanola, Vol. 64, Núm. 10, pp. 503-505